Jun. 3 at 9:15 AM
$ZBIO https://investors.zenasbio.com/news-releases/news-release-details/zenas-biopharma-announces-data-registrational-phase-3-indigo
Key Phase 3 Obexelimab Updates & Uplizna Comparison
Efficacy & Remission Metrics
--Complete Remission Quantified: At Week 52, 37.1% of obexelimab patients achieved complete remission (IgG4-RD Responder Index of 0 and no active disease) vs. 19.6% for placebo (p=0.0049).
--Flare Burden Reduction: Obexelimab cut the annualized adjudicated flare rate by 52% (p=0.0008), recording only 36 flares in the treatment group vs. 72 in the placebo arm.
--Comparison to Uplizna: While cross-trial comparisons have limitations, both assets demonstrate powerful flare reduction. Obexelimab's 56% overall flare risk reduction (HR= 0.44) establishes it as a highly potent front-line competitor capable of matching the clinical efficacy bar set by Amgen.
Steroid-Sparing & Toxicity Benefits
--65% Reduction in Steroid Use: Obexelimab-treated patients required a mean cumulative glucocorticoid rescue dose of only 329.5 mg over 52 weeks, compared to 929.8 mg for the placebo group (p=0.0042).
--Mitigation of Steroid Toxicity: Worsening of steroid-induced toxicities (measured by the Glucocorticoid Toxicity Index) was significantly lower with obexelimab, with only 28.9% of patients hitting severe toxicity thresholds vs. 49.4% on placebo (p=0.0090).
--Comparison to Uplizna: This quantified, hard-data reduction in steroid toxicity provides Zenas with a major marketing angle. Furthermore, unlike intravenously infused Uplizna, subcutaneous obexelimab does not require routine steroid premedication (prophylaxis) prior to dosing, further lowering a patient's chronic steroid exposure.
Safety & Mechanism Differentiators
--Favorable Infection Profile: The incidence of infections was actually lower in the obexelimab group (53.6%) than in the placebo group (62.9%). Grade 3 adverse events were also lower on active drug (11.3% vs. 23.7%).
--B-Cell Kinetics Confirmed: Pharmacodynamic data proved the "non-depleting" mechanism; after a minor initial dip, mean B-cell levels stabilized and consistently remained above the Lower Limit of Normal (LLN).
--Comparison to Uplizna: This is obexelimab’s primary competitive moat. As a traditional B-cell depleter, Uplizna profoundly wipes out the B-cell population, carrying long-term risks of hypogammaglobulinemia and elevated chronic infection rates over time. Obexelimab's data proves it downregulates pathogenic B cells without destroying them, maintaining an intact baseline immune system and delivering a cleaner long-term safety profile.
